These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 207646)
1. Relationship between Epstein-Barr virus (EBV)-production and the loss of the EBV receptor/complement receptor complex in a series of sublines derived from the same original Burkitt's lymphoma. Klein G; Yefenof E; Falk K; Westman A Int J Cancer; 1978 May; 21(5):552-60. PubMed ID: 207646 [TBL] [Abstract][Full Text] [Related]
2. Correlated expression of a B-lymphocyte-specific glycoprotein (gp27/35) and the EBV receptor/C3 receptor complex in sublines from the same Burkitt lymphoma. Klein G; Hyman R; Trowbridge I Int J Cancer; 1979 Jan; 23(1):37-41. PubMed ID: 215562 [TBL] [Abstract][Full Text] [Related]
3. Somatic cell hybrids between human lymphoma cell lines. V. IdUrd inducibility and P3HR-1 superinfectability of Daudi/HeLa (DAD) and Daudi/P3HR-1 (DIP-1) cell lines. Moar MH; Ber R; Klein G; Westman A; Eriksson I Int J Cancer; 1978 Dec; 22(6):669-74. PubMed ID: 82545 [TBL] [Abstract][Full Text] [Related]
4. Studies on the B lymphoblast antigen No. 1 (BB-1) on a series of Burkitt lymphoma lines differing in the expression of the EBV/C3 receptor complex. Ehlin-Henriksson B; Clark EA; Jønsson V; Klein G J Immunol; 1983 May; 130(5):2448-52. PubMed ID: 6187858 [TBL] [Abstract][Full Text] [Related]
5. Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1). Klein G; Zeuthen J; Eriksson I; Terasaki P; Bernoco M; Rosén A; Masucci G; Povey S; Ber R J Natl Cancer Inst; 1980 Apr; 64(4):725-38. PubMed ID: 6245297 [TBL] [Abstract][Full Text] [Related]
6. Column separation of viral capsid antigen (VCA)-positive cells from VCA-negative cells in an Epstein-Barr virus (EBV)-producing lymphoid line, Dalianis T; Klein G; Andersson B Int J Cancer; 1977 Apr; 19(4):460-7. PubMed ID: 191413 [TBL] [Abstract][Full Text] [Related]
7. Differential expression of the major histocompatibility antigen complex (MHC) on a series of Burkitt's lymphoma lines. Yokochi T; Inoue Y; Iwata H; Miyadai T; Kimura Y Microbiol Immunol; 1987; 31(12):1209-15. PubMed ID: 2836712 [TBL] [Abstract][Full Text] [Related]
8. Activation and fixation of C3 by human B cell lines is enhanced by interferon-gamma and tumor necrosis factor alpha. Yefenof E; Algarra I; Ramos OF; Klein E Complement Inflamm; 1991; 8(5-6):271-80. PubMed ID: 1666351 [TBL] [Abstract][Full Text] [Related]
9. Fc and C3 receptor patterns on two EBV- negative Burkitt lymphoma lines during acute exposure to EBV (P3HR-1 substrain). Jønsson V; Klein G Eur J Cancer (1965); 1981 Feb; 17(2):161-5. PubMed ID: 6266834 [No Abstract] [Full Text] [Related]
10. Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines. Klein G; Zeuthen J; Terasaki P; Billing R; Honig R; Jondal M; Westman A; Clements G Int J Cancer; 1976 Nov; 18(5):639-52. PubMed ID: 62724 [TBL] [Abstract][Full Text] [Related]
11. Hybridization between a human epithelial line, infectable by Epstein-Barr virus, and Burkitt lymphoma lines: membrane properties, superinfectability, inducibility and tumorigenicity. Mitrani-Rosenbaum S; Ber R; Goldblum N; Povey S; Gamliel H; Ben-Bassat H Int J Cancer; 1982 Nov; 30(5):593-600. PubMed ID: 6295967 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen. Sairenji T; Reisert PS; Spiro RC; Connolly T; Humphreys RE J Exp Med; 1985 May; 161(5):1097-111. PubMed ID: 2580934 [TBL] [Abstract][Full Text] [Related]
13. Re-evaluation of a transforming strain of Epstein-Barr virus from the Burkitt lymphoma cell line, Jijoye. Sairenji T; Hinuma Y Int J Cancer; 1980 Sep; 26(3):337-42. PubMed ID: 6270005 [TBL] [Abstract][Full Text] [Related]
14. Recovery of transforming EBV from non-producer cells after superinfection with non-transforming P3HR-1 EBV. Fresen KO; Cho MS; zur Hausen H Int J Cancer; 1978 Oct; 22(4):378-83. PubMed ID: 212377 [TBL] [Abstract][Full Text] [Related]
15. Lysis of P3HR-1 cells induced to enter the viral cycle by antibody-dependent and independent immunological mechanisms. Kurakata S; Ramos OF; Klein G; Klein E Cell Immunol; 1989 Oct; 123(1):134-47. PubMed ID: 2550147 [TBL] [Abstract][Full Text] [Related]
16. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains. Klein G; Ehlin-Henriksson B; Schlossman SF J Immunol; 1983 Apr; 130(4):1985-9. PubMed ID: 6300235 [TBL] [Abstract][Full Text] [Related]
17. Somatic cell hybrids between human lymphoma lines. II. Spontaneous and induced patterns of the Epstein-Barr virus (EBV) cycle. Klein G; Clements G; Zeuthen J; Westman A Int J Cancer; 1976 Jun; 17(6):715-24. PubMed ID: 59708 [TBL] [Abstract][Full Text] [Related]
18. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Klein G; Giovanella B; Westman A; Stehlin JS; Mumford D Intervirology; 1975; 5(6):319-34. PubMed ID: 181343 [TBL] [Abstract][Full Text] [Related]
19. The Epstein-Barr virus receptor is distinct from the C3 receptor. Wells A; Koide N; Stein H; Gerdes J; Klein G J Gen Virol; 1983 Feb; 64 (Pt 2)():449-53. PubMed ID: 6300295 [TBL] [Abstract][Full Text] [Related]
20. Multiplicity-dependent biological and biochemical properties of Epstein-Barr virus (EBV) rescued from non-producer lines after superinfection with P3HR-1 EBV. Cho MS; Fresen KO; zur Hausen H Int J Cancer; 1980 Sep; 26(3):357-63. PubMed ID: 6270006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]